Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP3R

Molecular Cancer Therapeutics

Volumn 16, Issue 1, 2017, Pages 217-227

  Kang, Seokmin ^a   Hong, Jinpyo ^b   Lee, Jung Moo ^b,c   Moon, Hyo Eun ^d   Jeon, Borami ^b,e   Choi, Jungil ^f   Yoon, Nal Ae ^a   Paek, Sun Ha ^d   Roh, Eun Joo ^b,e   Lee, C Justin ^b,c,e   Kang, Sang Soo ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e University of Science and Technology (UST)   (South Korea)

^f Korea Institute of Toxicology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; RECEPTOR SUBTYPE; RYANODINE RECEPTOR 3; TRIFLUOPERAZINE; ANTINEOPLASTIC AGENT; CALCIUM; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PROTEIN BINDING;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER GRAFT; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL CULTURE; CELL MOTION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENDOPLASMIC RETICULUM; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM; CALMODULIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; GLIOBLASTOMA; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROTEIN BINDING; TRIFLUOPERAZINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85010029696     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0169-T     Document Type: Article

References (36)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
3. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007;64:458-78.
4. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17:iv1-iv62.
5. Kang SS, Han KS, Ku BM, Lee YK, Hong J, Shin HY, et al. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res 2010;70:1173-83.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
7. Komotar RJ, Otten ML, Moise G, Connolly ESJr.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma - a critical review. Clin Med Oncol 2008;2:421-2.
8. Dalton SO, Johansen C, Poulsen AH, Norgaard M, Sorensen HT, McLaughlin JK, et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 2006;95:934-9.
9. Chou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year followup study. Schizophr Res 2011;129:97-103.
10. Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999;58:1229-36.
11. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis 2013;34:2080-9.
12. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003;4:463-76.
13. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev 2004;1:CD003545.
14. Frankfurt OS, Sugarbaker EV, Robb JA, Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 1995;97:149-54.
15. Karmakar P, Natarajan AT, Poddar RK, Dasgupta UB. Induction of apoptosis by Phenothiazine derivatives in V79 cells. Toxicol Lett 2001;125:19-28.
16. Shin SY, Kim CG, Hong DD, Kim JH, Lee YH. Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87MG glioma cells. Exp Mol Med 2004;36:380-6.
17. Annabi B, Pilorget A, Bousquet-Gagnon N, Gingras D, Beliveau R. Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells. Biochem J 2001;359:325-33.
18. Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, Carter D, et al. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemother Pharmacol 1996;38:65-70.
19. Schleuning M, Brumme V, Wilmanns W. Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. Anticancer Res 1993;13:599-602.
20. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012;186:1180-8.
21. Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, et al. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013;119:293-303.
22. Vandonselaar M, Hickie RA, Quail JW, Delbaere LT. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat Struct Biol 1994;1:795-801.
23. Michikawa T, Hirota J, Kawano S, Hiraoka M, Yamada M, Furuichi T, et al. Calmodulin mediates calcium-dependent inactivation of the cerebellar type 1 inositol 1,4,5-trisphosphate receptor. Neuron 1999;23:799-808.
24. Taylor CW, Laude AJ. IP3 receptors and their regulation by calmodulin and cytosolic Ca2+. Cell Calcium 2002;32:321-34.
25. Nadif Kasri N, Bultynck G, Sienaert I, Callewaert G, Erneux C, Missiaen L, et al. The role of calmodulin for inositol 1,4,5-trisphosphate receptor function. Biochim Biophys Acta 2002;1600:19-31.
26. Clapham DE. Calcium signaling. Cell 2007;131:1047-58.
27. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 2011;11:609-18.
28. Santella L. The role of calcium in the cell cycle: facts and hypotheses. Biochem Biophys Res Commun 1998;244:317-24.
29. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003;24:719-36.
30. Verkhratsky A, Orkand RK, Kettenmann H. Glial calcium: homeostasis and signaling function. Physiol Rev 1998;78:99-141.
31. Shin S, Lee S. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Ther Clin Risk Manag 2014;10:875-83.
32. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132:438-42.
33. Flahavan EM, Sharp L, Bennett K, Barron TI. A cohort study of digoxin exposure and mortality in men with prostate cancer. BJU Int 2014;113:236-45.
34. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the international initiative for accelerated improvement of glioblastoma care. Oncotarget 2013;4:502-30.
35. Kast RE, Karpel-Massler G, Halatsch ME. CUSP9∗ treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 2014;5:8052-82.
36. Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 2012;122:2637-51.